Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|March 15, 2016
- Pharmaceutical Technology-03-15-2016
- Volume 2016 eBook
- Issue 1
Filling the Analysis Gap in the Move to Continuous Processing
Author(s)Jamie Clayton
The author discusses issues and best approaches for solid dosage form pharmaceuticals.
Advertisement
More pharmaceutical companies are becoming interested in continuous processing, but they may face an “analytics gap,” because continuous will require a different approach to analytics. The author discusses issues and best approaches for solid dosage form pharmaceuticals.
from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
Articles in this issue
over 10 years ago
Optimizing Tablet Compressionover 10 years ago
Excipient Quality and Selectionover 10 years ago
Modeling and Simulation Move Downstreamover 10 years ago
Unifying Excipient Databasesover 10 years ago
Establishing a New Performance Standard for HPMC CapsulesAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Advertisement
Advertisement